Philips Healthcare parent Royal Philips Electronics and coronary imaging developer Infraredx have announced a nonexclusive resale agreement.
Philips will sell Infraredx's true vessel characterization (TVC) imaging system alongside Philips' Allura interventional x-ray systems in North America and Europe.
The TVC intravascular imaging system uses near-infrared spectroscopy and intravascular ultrasound to visualize the presence of plaques, quantify the degree of vessel stenosis, and identify plaques prone to rupturing and causing blockages.
The resale agreement piggybacks on an earlier collaboration between Philips and Infraredx. In March of this year, the companies launched software to enable the integration of the TVC system with Philips' Allura Xper and AlluraClarity interventional x-ray systems.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
